Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Role of Negr1 in Modulating Neuroplasticity in Major Depression
2021-006800-34Phase 4Completed
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of venlafaxine in major depressive disorder (MDD) (2 arms), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoints: Change in Negr1 transcript (mRNA) concentration and Change in Negr1 protein concentration. Started Jan 2022; status: completed.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-006800-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006800-34.